Clinical TrialJul 23, 2026, 09:27 AM
Imunon IMNN-001 shows 14.7-month survival increase in ovarian cancer
AI Summary
Imunon announced new data on its DNA-based IL-12 immunotherapy, IMNN-001, for advanced ovarian cancer, which was featured at the inaugural AACR Conference on Drug Discovery and Development. The updated final results from the Phase 2 OVATION-2 study demonstrated a 14.7-month increase in median overall survival (45.1 vs. 30.4 months) compared to chemotherapy alone. Translational analyses also showed favorable immune responses, and IMNN-001 was safe and well-tolerated, supporting the ongoing pivotal Phase 3 OVATION-3 trial.
Key Highlights
- IMNN-001 data presented at the inaugural AACR D3 conference.
- Updated median overall survival increased by 14.7 months (45.1 vs. 30.4 months) in OVATION-2.
- Previous OVATION-2 data showed a 13-month median overall survival increase.
- IMNN-001 is administered weekly over a 6-month period.
- The OVATION-2 study included 112 patients with newly diagnosed advanced ovarian cancer.
- Translational analyses showed enhanced favorable ratios of CD8+/Tregs and CD8+/CD4+ cells.
- IMNN-001 was safe and well-tolerated, with no cytokine release syndrome.
- The pivotal Phase 3 OVATION-3 trial is rapidly recruiting.
Price Impact
More from IMNN